Showing results (51-60 of 223) with videos related to

Sort By:
Pageof 23
Lung Cancer (Amsterdam, Netherlands)|October 3, 2015
Angiopoietin-2 is a negative prognostic marker in small cell lung cancerIsrael Cañadas, Álvaro Taus, Xavier Villanueva, et al.
BMC Cancer|March 19, 2022
Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in SpainFederico Rojo, Esther Conde, Héctor Torres, et al.
International Journal of Molecular Sciences|February 26, 2022
MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer PatientsAndrea Santos, Ion Cristóbal, Jaime Rubio, et al.
Scientific Reports|January 26, 2017
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 geneEduardo Tormo, Anna Adam-Artigues, Sandra Ballester, et al.
Cancers|July 2, 2021
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer ModelsMarta Sanz-Álvarez, Ester Martín-Aparicio, Melani Luque, et al.
Gut|April 8, 2016
Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancerGemma Ferrer-Mayorga, Gonzalo Gómez-López, Antonio Barbáchano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerRosana Sáez, Miguel A Molina, Elizabeth E Ramsey, et al.
ESMO Open|July 13, 2019
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussionAnna S Berghoff, Beatriz Bellosillo, Christophe Caux, et al.
BMC Cancer|June 11, 2021
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenarioErnest Nadal, Dolores Bautista, Luis Cabezón-Gutiérrez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 13, 2024
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyRamon Colomer, Blanca González-Farré, Ana Isabel Ballesteros, et al.
Pageof 23